Study on Therapeutic Effects of Antiplatelet Drugs in Prevention of Occurrence and Inhibition of Progression of Diabetic Atherosclerosis - Study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC Study)

DAPC Study Steering Committee0 个研究点目标入组 400 人开始时间: 2005年10月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1 Patients with type 1 diabetes or secondary diabetes 2 Patients aged under 40 years old, or over 76 years old 3 Patients with severe ASO rated as Fontaine IIb or over 4 Patients with cerebrovascular disorders rated as Grade 4 or over in Modified Rankin Scale (Severe disorder which needs assistance for personal care and walk) 5 Patients with a medical history of angina or myocardial infarction 6 Patients with severe hepatic dysfunction (liver cirrhosis) or renal dysfunction (serum creatinine 1.5mg/dl) 7 Patients with congestive heart failure 8 Patients with bleeding tendency or bleeding 9 Patients with severe hematological abnormality 10 Patients with definite homologousfamilial hypercholesterolemia 11 Patients who have allergies or a medical history of hypersensitivity to the investigational drugs 12 Pregnant or lactating women, or women who wish to become pregnant 13 Others whom the investigator judges inappropriate as subjects for this study

发起方

DAPC Study Steering Committee